Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer

Next Previous
Trial Profile

A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezvilutamide (Primary) ; Bicalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CHART
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 24 Oct 2023 Results of post-hoc analysis assessing the association between achievement of deep prostate-specific antigen decline with survival outcomes in patients with high-volume mHSPC in the CHART trial, presented at the 48th European Society for Medical Oncology Congress.
  • 05 Sep 2022 Primary endpoint has been met (OS), as per Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top